| CuraSen
Health Care
$68.6Mtotal raised · 4 rounds on record
$5.8Mlatest round · Venture round · Aug 2024 · 2 yr ago
2backers · Alta Partners, Longitude Capital
15stories in the press
Overview
It's time to think again about therapies for psychiatric and neurodegenerative disease. At CuraSen, we are targeting these brain diseases with novel science and treatments so patients can THINK, AGAIN.
Funding and backers
Total raised
$68.6M
4 rounds on record
Latest round
$5.8M
Venture round · Aug 2024 · 2 yr ago
Backers
2
Alta Partners, Longitude Capital
The money's age
Long since its last round
26 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 26, 2024
Raised a round Venture round $5.8M · SEC Form D
Nov 1, 2022
Raised a round Venture round $17.6M · SEC Form D
Oct 21, 2021
Raised a round Venture round $18M · SEC Form D
Sep 18, 2018
Raised a round Venture round $27.2M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Aug 2024 | $5.8M | — | SEC Form D |
| Venture round | Nov 2022 | $17.6M | — | SEC Form D |
| Venture round | Oct 2021 | $18M | — | SEC Form D |
| Venture round | Sep 2018 | $27.2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | CuraSen Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Anthony FordExecutive Officer, DirectorSEC Form D
Benjamin PotterExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Think you know soda? Think again. Meet Cove — zero sugar, probiotic function and nostalgic flavor you’ll actually crave.
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
FMH is simplifying specialty pharmacy care across providers, pharmacies, payers, and pharma—so patients don’t have to chase the care they…
Advancing Accessible Solutions for Complex Neurodegenerative Diseases. Protecting neurons to advance treatment for neurodegenerative…
Innovative therapeutics that target serious viral and liver diseases Assembly Bio is applying our passion, scientific ingenuity and deep…
CND advances neurodiagnostics through skin biopsy testing, including the Syn-One Test, for neurodegenerative diseases.
Financials
Total raised
$68.6M
Latest round
Venture - Series Unknown
Funding rounds
4
People
Anthony Ford
Executive Officer, Director
Benjamin Potter
Executive Officer
Kathleen Glaub
Director
Ron Hunt
Director
Patrick Enright
Director
Loretta Tse Ph.D.
Director
Simon Tate Ph.D.
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Alta PartnersVia a fund
Longitude CapitalVia a fund
78 portfolio companies: Zenas BioPharma, Mobia Medical, Inc. and 76 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium
SAN CARLOS, Calif., November 10, 2025--CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced encouraging results from a Phase 1 study
Read more
Report
CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium
Data support ongoing Phase 2a study with CuraAX in patients with neurogenic orthostatic hypotension (nOH) to prevent severe decreases in cerebral blood flow and cognition San Carlos, CA, - November 10, 2025 - CuraSen Therapeutics, Inc., a biopharmaceutica
Read more
Report
CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study
CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH San Carlos, CA, - October 23, 2025 - CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neuro
Read more
Report
CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial
CuraAX Designed to Treat Neurogenic Orthostatic Hypotension (nOH) and Cognitive Impairment San Carlos, CA - February 20, 2025 - CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to tr
Read more
Report
CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer
Expands Adrenergic Pipeline to Address Neurogenic Orthostatic Hypotension and Major Depressive Disorder in Older Adults San Carlos, CA, 2024 - October 15, 2024 - CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid
Read more
Report
CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer's or Parkinson's Disease at AD/PD 2024 International Conference
Drug Combination's Unique Mechanism of Action Enables Reactivation of Brain Adrenergic Function, Showing Improvements in Multiple Areas of Cognition San Carlos, CA and Lisbon, Portugal, March 7, 2024 - CuraSen Therapeutics, Inc., a clinical-stage company
Read more
Report
CuraSen Presents Late-Breaking Phase 2 Data with CST-2032/CST-107 at Clinical Trials in Alzheimer's Disease (CTAD) Conference
The post CuraSen Presents Late-Breaking Phase 2 Data with CST-2032/CST-107 at Clinical Trials in Alzheimer's Disease (CTAD) Conference appeared first on CuraSen.
Read more
Report
CuraSen Therapeutics Announces Strategic Investment from the Alzheimer's Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer's Disease
October 9, 2023, San Mateo, CA - CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has received a strategic investment of up to $5.8 million from the Alzheimer's
Read more
Report
CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson's Disease at the Alzheimer's Disease and Parkinson's Disease (AD/PD'23) Conference
Additional Phase 1 Data with CST-2032/CST-107 Reinforce Potential of Adrenoceptor Agonist Class of Drugs in Patients with Cognitive Impairment March 30, 2023 - Gothenburg, Sweden - CuraSen Therapeutics, Inc., a clinical-stage company developing small mole
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Carlos
United States
HQ